Bristol-Myers Squibb faces revenue declines but offers long-term potential via growth drugs. Read what BMY stock has to offer ...

At recent prices, the yield you receive from Pfizer is more than four times the amount you'd receive from the average ...

Bristol Myers Squibb (BMY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

The U.S. Food and Drug Administration said on Friday it had eliminated risk evaluation and mitigation strategies (REMS), a ...

Onco360®, the nation’s leading independent specialty pharmacy, has added Augtyro™ (repotrectinib) manufactured by Bristol ...

Looking into the current session, Bristol-Myers Squibb Inc. BMY shares are trading at $47.05, after a 1.22% drop. Over the ...

Long-term follow-up data show that the preventive effects of short-term treatment with abatacept disappear after 4-5 years.

Bristol Myers Squibb (BMY) closed at $47.51 in the latest trading session, marking a +2.64% move from the prior day.

BMY’s robust launch portfolio, resilient free cash flow, and above-consensus growth outlook position it for outsized returns ...

Bristol Myers Squibb to cut 68 jobs in Lawrenceville as part of a broader restructuring effort aiming to slash $2B in costs ...